In addition, our findings of reactivation of the MEK/ERK pathway in the LY3009120-resistant cell line are in line with recent studies examining clinical acquired resistance of BRAFmut CRC to RAF inhibitor combinations due to genetic alterations in the MAPK pathway [9]. This evidence concerns the gene RAF1 and colorectal carcinoma.